Theracryf Plc Stock Price

AIM:TCF Community·UK£4.5m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

TCF Share Price Performance

UK£0

-0.01 (-100.00%)

UK£0

-0.01 (-100.00%)

UK£0

Mon, 12 Jan 26

Share Pricen/a

TCF Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

1 Reward

View Full Analysis

Theracryf Plc Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -0.00093
: 0%
: 0%
: 0%

View Full Analysis

About TCF

Founded: 2014
Employees: 9
CEO: Huw Jones
WebsiteView website: theracryf.com

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.